Zhejiang Tianyu Pharmaceutical Co Ltd
SZSE:300702
Intrinsic Value
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical raw materials and intermediates. [ Read More ]
The intrinsic value of one Zhejiang Tianyu Pharmaceutical Co Ltd stock under the Base Case scenario is 21.79 CNY. Compared to the current market price of 17.78 CNY, Zhejiang Tianyu Pharmaceutical Co Ltd is Undervalued by 18%.
Valuation Backtest
Zhejiang Tianyu Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling Zhejiang Tianyu Pharmaceutical Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Zhejiang Tianyu Pharmaceutical Co Ltd
| Current Assets | 3B |
| Cash & Short-Term Investments | 434.1m |
| Receivables | 515m |
| Other Current Assets | 2B |
| Non-Current Assets | 3.4B |
| Long-Term Investments | 93.4m |
| PP&E | 2.8B |
| Intangibles | 424.6m |
| Other Non-Current Assets | 60.7m |
| Current Liabilities | 2.6B |
| Accounts Payable | 359.7m |
| Accrued Liabilities | 67m |
| Short-Term Debt | 2B |
| Other Current Liabilities | 186.7m |
| Non-Current Liabilities | 233.2m |
| Long-Term Debt | 157.8m |
| Other Non-Current Liabilities | 75.5m |
Earnings Waterfall
Zhejiang Tianyu Pharmaceutical Co Ltd
|
Revenue
|
2.4B
CNY
|
|
Cost of Revenue
|
-1.6B
CNY
|
|
Gross Profit
|
852.2m
CNY
|
|
Operating Expenses
|
-792.7m
CNY
|
|
Operating Income
|
59.5m
CNY
|
|
Other Expenses
|
-148.4m
CNY
|
|
Net Income
|
-88.9m
CNY
|
Free Cash Flow Analysis
Zhejiang Tianyu Pharmaceutical Co Ltd
Profitability Score
Profitability Due Diligence
Zhejiang Tianyu Pharmaceutical Co Ltd's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Zhejiang Tianyu Pharmaceutical Co Ltd's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Zhejiang Tianyu Pharmaceutical Co Ltd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Zhejiang Tianyu Pharmaceutical Co Ltd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Zhejiang Tianyu Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for Zhejiang Tianyu Pharmaceutical Co Ltd is 26.52 CNY with a low forecast of 26.26 CNY and a high forecast of 27.3 CNY.
Shareholder Return
Price
Zhejiang Tianyu Pharmaceutical Co Ltd
| Average Annual Return | 18.64% |
| Standard Deviation of Annual Returns | 60% |
| Max Drawdown | -80% |
| Market Capitalization | 6.1B CNY |
| Shares Outstanding | 347 977 159 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical raw materials and intermediates. The company is headquartered in Taizhou, Zhejiang and currently employs 4,991 full-time employees. The company went IPO on 2017-09-19. The firm operates three segments. The Pharmaceutical Intermediates segment include hypertension drugs raw materials, anti-asthma drugs raw materials and anticoagulant drugs raw materials. The Active Pharmaceutical Ingredients (API) segment is engaged in production of high blood pressure drug intermediates, anti-asthma drug intermediates and antiviral drug intermediates. The firm also operates Other segment. The firm sells its products to both domestic and international markets, including Europe, the United States, Japan, South Korea and so on.
Contact
IPO
Employees
Officers
The intrinsic value of one Zhejiang Tianyu Pharmaceutical Co Ltd stock under the Base Case scenario is 21.79 CNY.
Compared to the current market price of 17.78 CNY, Zhejiang Tianyu Pharmaceutical Co Ltd is Undervalued by 18%.
You don't have any saved screeners yet
